Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer

Summary

This study investigated the associations between clinicopathological characteristics and genetic alterations in breast cancer, focusing on how clinical and pathological variables influence the actionability of Next Generation Sequencing (NGS) data. Among 227 breast cancer patients, comprehensive genomic profiling revealed that a vast majority (95.6%) harbored at least one oncogenic alteration. Subtype-specific patterns were identified, with an enrichment of PIK3CA and ESR1 alterations in HR+/HER2- tumors, and a predominance of TP53 in triple-negative breast cancer. The study highlights that NGS-based genomic profiling identifies clinically actionable alterations in over half of breast cancer patients, particularly in the HR+/HER2- subtype, and supports its routine implementation, especially for metastatic HER2-negative breast cancer.

Critical appraisal

This retrospective cohort study highlights a high clinical actionability of genomic alterations in breast cancer, with 60% "on-label" alterations in HR+/HER2- tumors. The inclusion of tumor-agnostic biomarkers like TMB and MSI increased this actionability to 64.5% in this subtype. These findings justify the integration of comprehensive NGS-based genomic profiling into routine clinical practice, especially for metastatic HER2-negative breast cancer, to guide precision oncology strategies and enrollment in biomarker-driven clinical trials. Clinical impact could be observed in the medium term (3-5 years) with improved treatment selection and access to targeted therapies or trials.

The research utilized a 1021-gene NGS-based multigene panel to characterize the tumor mutational landscape. This approach led to the discovery of subtype-specific alteration patterns, notably the enrichment of PIK3CA and ESR1 alterations in HR+/HER2- tumors, and the predominance of TP53 in triple-negative breast cancer. The use of tumor molecular profiling data demonstrates high analytical validity with a diagnostic yield of 95.6% for detecting oncogenic alterations. These discoveries pave the way for validated clinical tests for these biomarkers to stratify patients.

The study relies on the analysis of large-scale genomic data generated by a 1021-gene NGS panel. Bioinformatic analysis is essential for processing raw sequencing data, variant identification, TMB quantification, and MSI status assessment. These analyses enable the correlation of genetic alterations with clinicopathological characteristics, which is crucial for clinical interpretation. The clinical deployment of such bioinformatic analyses would allow for prioritizing patients for molecular tumor boards and optimizing the selection of targeted treatments.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology